Prostate cancer is the most common cancer in Australia, with about 26,000 men diagnosed per year. The majority (more than 85%) are aged over 60. In males, prostate cancer can be identified through a ...

A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced ...

PSA tests may also give false positive results when someone doesn't have cancer. Prostate cancer is the most common cancer in Australia, with 26,000 diagnoses yearly PSA testing reduces prostate ...

The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate ...

The Prostate Specific Antigen (PSA) Testing market refers to the sector involved in the development, production, and distribution of diagnostic tests that detect levels of PSA in the blood, a key ...

Prostate cancer is the malignant growth of cells in the prostate, a walnut-sized gland below the bladder, that is responsible for producing semen. The majority of prostate cancers develop at a slow ...

Prostate cancer is one of the most common cancers affecting men around the world. It develops in the prostate, a small gland ...

A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage trial investigated a form of radiotherapy on patients who had stopped ...

Prostate cancer screening saves many more lives than earlier studies suggested, research shows. The results from the longest-running European trial show one life saved for every six men diagnosed, a ...

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...